Early research (Phase 1)UnknownNCT04441918
What this trial is testing
Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects
Who this might be right for
COVID-19; and High Infection Risk of SARS-CoV-2
Shanghai Junshi Bioscience Co., Ltd. 40